Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating on AstraZeneca shares with a target price of 11,500 pence, slightly below the current trading price. The data follows AstraZeneca's raised peak sales guidance above $5 billion, with consensus forecasts around $4 billion for 2030, suggesting room for modest upward revisions. The next key event will be analysts' reassessment of tozorakimab's revenue potential based on detailed COPD findings.
AstraZeneca's phase III trial results for tozorakimab in treating chronic obstructive pulmonary disease (COPD) showed significant reduction in flare-ups, especially in former smokers. The drug met its primary endpoint with a 29% to 34% reduction in e...
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
AstraZeneca released full data from two late-stage trials of its experimental COPD drug, tozorakimab, showing significant reduction in flare-ups among both former and current smokers. The drug, under FDA priority review with expected approval in earl...
AstraZeneca's drug Etcamah (camizestrant) received accelerated FDA approval for use with CDK4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer patients with ESR1 mutations. This approval follows earlier European clear...
